Event, FDA Approval, Positive Results, Partnership, and Marketing Authorization - Research Report on Pfizer, Merck, Bristol

      Event, FDA Approval, Positive Results, Partnership, and Marketing
Authorization - Research Report on Pfizer, Merck, Bristol-Myers Squibb, Lilly,
                                   and GSK

PR Newswire

NEW YORK, September 9, 2013

NEW YORK, September 9, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Investors' Reports announced new research reports highlighting Pfizer
Inc. (NYSE: PFE), Merck & Co. Inc. (NYSE: MRK), Bristol-Myers Squibb Company
(NYSE: BMY), Eli Lilly and Company (NYSE: LLY), and GlaxoSmithKline plc (NYSE:
GSK). Today's readers may access these reports free of charge - including full
price targets, industry analysis and analyst ratings - via the links below.

Pfizer Inc. Research Report

On September 3, 2013, Pfizer Inc. (Pfizer) announced its participation in the
upcoming Morgan Stanley Global Healthcare Conference on Tuesday, September 10,
2013. According to the Company, Frank D'Amelio, Executive Vice President of
Business Operations and CFO, will hold a discussion during the event, and
Pfizer invites investors and general public to listen to its webcast scheduled
to begin at 4:05 p.m. EDT. Pfizer further informed that the webcast can be
accessed by clicking on the "Morgan Stanley Global Healthcare Conference" link
in its Investor Relations website. The Full Research Report on Pfizer Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.InvestorsReports.com/report/2013-09-04/PFE]

--

Merck & Co. Inc. Research Report

On September 4, 2013, Merck & Co. Inc. (Merck) announced that it has received
the US FDA approval to manufacture bulk varicella at the Company's site in
Durham, North Carolina. Pfizer reported that the FDA approval will enable the
site to produce bulk varicella supply for the US, for use in Merck's vaccines
to protect against chickenpox and shingles, and help boost Merck's overall
global supply capabilities. Julie Gerberding, M.D., President of Merck
Vaccines, stated, "This is an important step forward in our long-term strategy
to reach more and more people around the world with Merck's vaccines." The
Full Research Report on Merck & Co. Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.InvestorsReports.com/report/2013-09-04/MRK]

--

Bristol-Myers Squibb Company Research Report

On September 2, 2013, Bristol-Myers Squibb Company (Bristol-Myers Squibb) and
AstraZeneca announced the SAVOR clinical trial results, which was conducted
over 16,492 adult patients with type 2 diabetes at high risk for
cardiovascular events. The Companies reported that the primary safety
objective was met by Onglyza (saxagliptin), demonstrating no increased risk
for the primary composite endpoint of cardiovascular death, non-fatal
myocardial infarction (MI) or non-fatal ischemic stroke, when added to a
patient's current standard of care (with or without other anti-diabetic
therapies), as compared to placebo. Furthermore, the Company informed that
Onglyza did not meet the primary efficacy endpoint of superiority to placebo
for the same composite endpoint. Brian Daniels, MD, Senior Vice President of
Global Development and Medical Affairs, Research and Development at
Bristol-Myers Squibb, commented, "No other DPP-4 inhibitor and few other
anti-hyperglycemic agents have been studied as extensively as Onglyza to
address the question of cardiovascular safety." Daniels added, "Bristol-Myers
Squibb and AstraZeneca are dedicated to meeting needs of physicians and
patients in diabetes care and helping to ensure a better understanding of the
value of our medications." The Full Research Report on Bristol-Myers Squibb
Company - including full detailed breakdown, analyst ratings and price targets
- is available to download free of charge at:
[http://www.InvestorsReports.com/report/2013-09-04/BMY]

--

Eli Lilly and Company Research Report

On August 29, 2013, Eli Lilly and Company (Lilly) announced its joint research
collaboration with Humana Inc. (Humana). According to Lilly, its partnership
with Humana reflects a shared commitment by both the Companies to address the
challenges of improving quality of care and reducing treatment costs in
today's complex and changing health care environment. William Fleming,
Pharm.D., President of Humana Pharmacy Solutions, said, "Pairing Humana's
clinical expertise and rich, de-identified patient data with Lilly's history
and experience across many disease states allows us to maximize the potential
benefits for patient care and savings." Fleming continued, "By leveraging our
collective capabilities, we can work to address the critical health care needs
facing our country." The Full Research Report on Eli Lilly and Company -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.InvestorsReports.com/report/2013-09-04/LLY]

--

GlaxoSmithKline plc Research Report

On September 2, 2013, GlaxoSmithKline plc (GSK) announced that its Tafinlar
(dabrafenib) has been granted a marketing authorization by the European
Commission. GSK reported that Tafinlar is an oral targeted treatment indicated
in monotherapy for unresectable melanoma (melanoma that cannot be removed by
surgery) or metastatic melanoma (melanoma which has spread to other parts of
the body) in adult patients with a BRAF V600 mutation. Paolo Paoletti, M.D.,
President of GlaxoSmithKline Oncology, stated, "Today's authorisation of
Tafinlar represents an important step in GSK's ongoing effort to bring new
treatment options to cancer patients, especially as we have brought it to
market in less than five years after our initial testing." Paoletti continued,
"With this new personalised medicine, we hope to make a meaningful difference
in the lives of appropriate patients with metastatic melanoma; a devastating
disease and a cancer with one of the lowest survival rates." The Full Research
Report on GlaxoSmithKline plc - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.InvestorsReports.com/report/2013-09-04/GSK]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by an analyst. However, we are only human and are prone
    to make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through analysts, only reviewed
the information provided by Equity News Network in this article or report
according to the Procedures outlined by Equity News Network. Equity News
Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

InvestorsReports.com

SOURCE Investors' Reports

Contact: Kristi Saunders CONTACT PHONE: +1-315-982-6420 (North America)
 
Press spacebar to pause and continue. Press esc to stop.